Quick Answer
BioNexus Gene Lab Corp reported Gross Profit of $1.29 million for the year ending 2024.
- BioNexus Gene Lab Corp showed a decrease of -3.0% in Gross Profit from 2023 to 2024.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$12.5 thousand | Q2 2018: $25.7 thousand | Q3 2018: $22.4 thousand | Q1 2019: $9.3 thousand | Q2 2019: $4.6 thousand | Q3 2019: $7.7 thousand | Q1 2020: $655.3 thousand | Q2 2020: $159.3 thousand | Q3 2020: $522.2 thousand | Q1 2021: $582.6 thousand | Q2 2021: $467.6 thousand | Q3 2021: $709.2 thousand | Q1 2022: $356.3 thousand | Q2 2022: $264.0 thousand | Q3 2022: $299.5 thousand | Q1 2023: $368.9 thousand | Q2 2023: $339.7 thousand | Q3 2023: $354.3 thousand | Q1 2024: $365.0 thousand | Q2 2024: $288.7 thousand | Q3 2024: $326.5 thousand | Q1 2025: $343.5 thousand | Q2 2025: $368.0 thousand | Q3 2025: $377.7 thousand.
- Over the full 7 years of available data (2018 to 2024), BioNexus Gene Lab Corp's Gross Profit has grown by 4,383.0%.
- Historical annual values: Fiscal year 2024: $1.29 million | Fiscal year 2023: $1.33 million | Fiscal year 2022: $1.26 million | Fiscal year 2021: $2.27 million | Fiscal year 2020: $1.72 million | Fiscal year 2019: $55.9 thousand | Fiscal year 2018: $28.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: